TAKE CONTROL HIGH LEVEL
|
|
- Noah Anthony
- 5 years ago
- Views:
Transcription
1 TAKE CONTROL TO A HIGH Clyton, 34 yers old, is pilot who hikes nd cmps in his spre time. Clyton lives with hemophili B. LEVEL Reinyn Rech for high fctor levels in hemophili B 1 Json, 8 yers old, spends his time plying outdoors. Json lives with hemophili B. All imges of hemophili B ptients shown re for illustrtive purposes only. INDICATIONS AND USAGE Reinyn, Cogultion Fctor IX (Recominnt), GlycoPEGylted, is recominnt DNA derived cogultion Fctor IX concentrte indicted for use in dults nd children with hemophili B for on demnd tretment nd control of leeding episodes nd periopertive mngement of leeding. Limittions of Use: Reinyn is not indicted for routine prophylxis or for immune tolernce induction in ptients with hemophili B. Plese see dditionl Importnt Sfety Informtion throughout nd on pges 12 nd 13.
2 2 TAKE CONTROL WITH HIGH FACTOR ACTIVITY In phse 3 study of dults with 2% fctor levels, single dose of Reinyn 40 IU/kg ws shown to Elevte fctor levels ove seline levels 1, +94 % 17 % ACHIEVE HIGHER FACTOR ACTIVITY FOR LONGER In phse 1 study, compred to stndrd hlf-life (SHL) FIX, Reinyn ws shown to 2,c Increse FIX ctivity Prolong time in the ody Keep FIX ctivity higher 2x 5x 10x Recovery rte 2,c Hlf-life 2,c Are under the curve 2,c 3 Phrmcokinetics Reinyn : 1.31% d SHL rfix: 0.68% d Reinyn : 93 hours SHL rfix: 19 hours Reinyn : 72 e SHL rfix: 7 e d Per IU/kg. e (U x h/ml). chieved fter n infusion 1, sustined fter 7 dys 1, Bsed on phrmcokinetic ssessment of single dose of Reinyn 40 IU/kg in 6 dults (men FIX ctivity 16.8%), 3 dolescents (men FIX ctivity 14.6%), 13 children ges 7 to 12 (men FIX ctivity 10.9%), nd 12 children ges 0-6 (men FIX ctivity 8.4%) upon enrollment in the phse 3 trils using one-stge ssy nd product-specific stndrd. All vlues re geometric men. Bsed upon 2.34% increse in fctor levels per IU/kg infused in dults. Reinyn chieved n 83-hour men hlf-life in dults 1, 2x THE RECOVERY RATE Reinyn chieved nd mintined higher fctor ctivity 2,c FIX Activity (%) x THE HALF-LIFE Time (hours) 10x THE AREA UNDER THE CURVE Reinyn SHL rfix IMPORTANT SAFETY INFORMATION Contrindictions Reinyn is contrindicted in ptients with known hypersensitivity to Reinyn or its components, including hmster proteins. Wrnings nd Precutions Hypersensitivity rections, including nphylxis, my occur. Signs my include ngioedem, chest tightness, difficulty rething, wheezing, urticri, nd itching. Discontinue Reinyn if llergic or nphylctic-type rections occur nd initite pproprite tretment. Plese see dditionl Importnt Sfety Informtion throughout nd on pges 12 nd 13. In this study, the estimted time to 1% with Reinyn ws 22.5 dys 2,c c Bsed upon phse 1 study of ptients dministered one of three doses of Reinyn (25, 50 or 100 IU/kg) compred with one 50 IU/kg dose of their prior SHL rfix (n=7) or pdfix (n=8) using one-stge ssy nd product-specific stndrd. For Reinyn, estimted men ctivity is djusted to dose of 50 IU/kg. Differences were similr in comprison of Reinyn to pdfix (recovery 1.3 vs 1.1 IU/dL per IU/kg, 1.2x; hlf-life 93 vs 18 hours, 5.2x; AUC 70 vs 9 U x h/ml, 8x). Reinyn is not pproved for routine prophylxis. Animls given repet doses of Reinyn showed ccumultion of PEG in the choroid plexus. The potentil clinicl implictions of these niml findings re unknown.
3 4 5 ACHIEVE CONTROL WHEN BLEEDS OCCUR PROTECTION FROM A SINGLE DOSE DURING SURGERY 98 % leeds treted with 1-2 infusions 1 n=143 leeding episodes Single In ll mjor surgeries studied 1,c 80 IU/kg 100 % Efficcy: On-demnd & Surgery preopertive dose 1 intropertive success rte 1 95 % rted their leed control s successful (defined s excellent or good) 1, n=142 leeding episodes c Results shown re from the surgery tril, which included 13 previously treted dolescent nd dult sujects. On the dy of their respective surgeries, ptients received 1 infusion of Reinyn 80 IU/kg. Postopertively, sujects received infusions of Reinyn 40 IU/kg t the investigtor s discretion for up to 3 weeks fter surgery. Across 13 surgicl procedures (9 mjor) which included 9 orthopedic, 1 gstrointestinl, nd 3 orl cvity procedures the hemosttic effect during surgery ws evluted on 4-point scle of excellent, good, moderte, or poor. Tretment success ws defined s excellent or good hemostsis. FIX ctivity sustined up to 48 hours postsurgery 1,3,d Results shown re from the on-demnd rm of the dolescent/ dult tril, in which 15 previously treted dolescent/dult sujects were treted for on-demnd leeds. In 14 sujects, there were totl of 143 leeding episodes. In 1 suject, no leeding episode dt were recorded. Results shown re sed on leed ssessment y either the ptient (for home tretment) or the study investigtor (for tretment under medicl supervision). Bleeds were ssessed using 4-point scle of excellent, good, moderte, or poor. FIX Activity, % Norml FIX ctivity rnge (50% to 150%) 4,e Json, 8 yers old, spends his time plying outdoors. Json lives with hemophili B Time (h) Wrnings nd Precutions (cont d) Development of neutrlizing ntiodies (inhiitors) to Fctor IX my occur. Monitor ptients for development of fctor IX inhiitors if leeding is not controlled with the recommended dose of Reinyn or if expected Fctor IX ctivity plsm levels re not ttined. Fctor IX ctivity ssy results my vry with the type of ctivted prtil thromoplstin time regent used. Plese see dditionl Importnt Sfety Informtion throughout nd on pges 12 nd 13. d In the surgery study, men FIX ctivity following n initil preopertive Reinyn 80 IU/kg in 13 procedures ws ssessed y one-stge ssy with product-specific stndrd. At 8 nd 24 hours, one suject who hd no FIX ctivity mesurement otined ws excluded. At 48 hours, 2 sujects who hd no FIX ctivity mesurement otined were excluded nd 4 sujects re-dosed prior to the second dy fter surgery for whom FIX ctivity t 24 hours were 84%, 112%, 131%, nd 134%. The FIX ctivity t 48 hours reflects mesurement on the second dy fter surgery (rnge hours). e Rnge shded represents the norml popultion FIX ctivity rnge of 50% to 150%.
4 6 7 TAKE CONTROL WITH SIMPLIFIED DOSING FAST INFUSIONS AND FLEXIBLE STORAGE Unlike other FIX products, there is no need to clculte desired FIX ctivity levels when determining the pproprite dose 1,5-9 The recommended dose for ll ptients is Reinyn cn e infused in 1-4 MINUTES 1 With MixPro, prepring dose of Reinyn is s quick s A single dose should e sufficient for minor nd moderte leeds. Additionl doses of 40 IU/kg cn e given. 40 IU/kg for minor or moderte leeds 1, 80 IU/kg for mjor leeds FPO ATTACH 1, Prefilled diluent syringe contins 4 ml of diluent works with ny dose strength TWIST 1, Adpter connects the syringe nd vil, with 25 μm inline prticle filter Dosing nd Administrtion MIX 1, After mixing, the reconstituted solution cn e dministered Mrkus, 33 yers old, spends his time with his fmily nd plying pool. Mrkus lives with hemophili B. For complete instructions on reconstitution nd dministrtion, plese refer to the Instructions for Use. 500 No refrigertion required (up to 86 F) 1,c Wrnings nd Precutions (cont d) The use of Fctor IX-contining products hs een ssocited with thromotic complictions. Monitor for thromotic nd consumptive cogulopthy when dministering Reinyn to ptients with liver disese, post-opertively, to neworn infnts, or to ptients t risk of thromosis or disseminted intrvsculr cogultion (DIC). Nephrotic syndrome hs een reported following immune tolernce induction therpy with Fctor IX products in hemophili B ptients with Fctor IX inhiitors, often with history of llergic rections to Fctor IX. The sfety nd efficcy of using Reinyn for immune tolernce induction hve not een estlished. Plese see dditionl Importnt Sfety Informtion throughout nd on pges 12 nd 13. Room temperture stle for up to 6 months c If you choose to store Reinyn t room temperture, do not return it to the refrigertor. Reinyn vils cn lso e stored in the refrigertor t 36ºF-46ºF for up to 24 months or until the expirtion dte stted on the lel. Plese see Prescriing Informtion for complete storge instructions. Postreconstitution storge for up to 4 hours
5 8 9 DESIGNED FOR SAFETY ACHIEVE A LONG HALF-LIFE In clinicl trils, 115 previously treted mle ptients were given Reinyn for 8801 exposure dys 1 PEGyltion is technology used to extend hlf-life 12 0 Inhiitors nd thromotic events 1,10,11, Selective Attchment Prolonged Circultion Activted FIX Relese site-directed glycopegyltion Adverse rections include hypersensitivity (1%), itching (3%), nd injection-site rections (4%) 1, ctive FIX Formtion of inhiitors nd thromotic complictions hve een ssocited with FIX tretment. Monitor ptients for the development of inhiitors nd signs of thromosis 1 Identified in 115 previously treted ptients who were treted with Reinyn in clinicl studies. A previously treted ptient ws defined s suject with history of t lest 150 exposure dys to other FIX products (dolescent/dult sujects) or 50 exposure dys to other FIX products (peditric sujects) nd no history of inhiitors. There were totl of 8801 exposure dys, equivlent to 170 ptient-yers. A totl of 40 ptients (35%) were treted for more thn 2 yers. PEG selectively ttches to the FIX ctivtion peptide y site-directed glycopegyltion 13 PEG=polyethylene glycol. GlycoPEGyltion keeps Reinyn in the loodstrem longer where it needs to e to stop leeding 13 Reinyn releses rfix similr to ntive humn FIX once ctivted 1 Sfety Profile nd PEGyltion Leopoldo, 61 yers old, is n IT engineer who spends time siling. Leopoldo lives with hemophili B. Adverse Rections The most common dverse rections reported in clinicl trils ( 1%) were itching nd injection site rections. Plese see dditionl Importnt Sfety Informtion throughout nd on pges 12 nd 13. Adverse Rections (cont d) Animls dministered repet doses of Reinyn showed ccumultion of PEG in the choroid plexus. The potentil clinicl implictions of these niml findings re unknown.
6 10 11 INFORMATION FOR YOUR PATIENTS TRIAL PROGRAM Eligile ptients cn receive up to 1-month supply of Reinyn PRODUCT ASSISTANCE PROGRAM Apply for the Product Assistnce Progrm y clling NOVOSEC ( ) for more informtion CO-PAY ASSISTANCE PROGRAM Get help with co-py costs for Reinyn c Ptients who hve een prescried Novo Nordisk hemophili nd rre leeding disorder product for n FDA-pproved indiction, nd who hve commercil insurnce, my e eligile to receive limited supply of free product. Ptients who prticipte in ny government, stte, or federlly funded medicl or prescription enefit progrms, including Medicre, Medicid, Medigp, VA, DOD, nd TRICARE, including ptients who prticipte in mnged Medicid progrm or hve Medicid s secondry insurnce, re not eligile to receive product support. Product is provided t no cost to the ptient or the HCP, is not contingent on ny product purchse, nd the ptient nd HCP must not: (1) ill ny third prty for the free product, or (2) resell the free product. The Novo Nordisk Ptient Assistnce Progrm (PAP) is dministered y NovoSecure. To qulify for the PAP, ptients must demonstrte finncil need nd must hve ttempted to find lterntive reimursement. Severl fctors re considered in evluting finncil need, including cost of living, size of household, nd urden of totl medicl expenses. If the pplicnt qulifies under the PAP guidelines, limited supply of the requested mediction(s) will e shipped to the ptient. Ptients who qulify for PAP my e eligile to receive the prescried Novo Nordisk product, for up to 1 yer from the pprovl dte. Product limits vry. c Novo Nordisk Hemophili nd Rre Bleeding Disorders Co-py/Coinsurnce Terms nd Conditions: Enrolled ptients re eligile for up to $12,000 in co-py/coinsurnce ssistnce per clendr yer for ech NNI hemophili or rre leeding disorder product. Assistnce is retroctive to 60 dys. Ptients must e commercilly insured nd my not e prticipting in ny government, stte, or federlly funded medicl or prescription enefit progrms, including Medicre, Medicid, Medigp, VA, DOD, nd TRICARE, including ptients who prticipte in mnged Medicid progrm or hve Medicid s secondry insurnce. Uninsured, csh-pying ptients re not eligile to prticipte. Ptients re eligile to receive co-py/coinsurnce ssistnce on n nnul sis (12 months). Offer good only in the USA, Puerto Rico, Gum, Sipn, nd Virgin Islnds with prticipting phrmcies nd cnnot e redeemed t governmentsusidized clinics. Void where txed, restricted, or prohiited y lw. Asent chnge in Msschusetts lw, effective July 1, 2019, the Svings Crd will no longer e vlid for residents of Msschusetts. Ptient is responsile for complying with ny insurnce crrier co-pyment disclosure requirements, including disclosing ny svings received from this progrm. Re-confirmtion of informtion my e requested periodiclly to ensure ccurcy of dt nd complince with terms. This is not n insurnce progrm. Novo Nordisk reserves the right to rescind, revoke, or mend this offer without notice t ny time. Non-mediction expenses, such s ncillry supplies or dministrtion-relted costs, re not eligile. Must hve current prescription for n FDA-pproved indiction. Visit MyNovoSecure.com or cll NOVOSEC ( ) to spek with NovoSecure Specilist Support Plese see Importnt Sfety Informtion throughout nd on pges 12 nd 13.
7 ACHIEVE CONTROL WHEN BLEEDS OCCUR IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE Adverse Rections Reinyn, Cogultion Fctor IX (Recominnt), GlycoPEGylted, is recominnt DNA derived cogultion Fctor IX concentrte indicted for use in dults nd children with hemophili B for on demnd tretment nd control of leeding % mngement leeds treted with 1-2 infusions1 episodes nd periopertive of leeding. leeding episodesprophylxis indicted for routine or for immune Limittions of Use: Reinyn is notn=143 tolernce induction in ptients with hemophili B. The most common dverse rections reported in clinicl trils ( 1%) were itching nd injection site rections. Animls dministered repet doses of Reinyn showed ccumultion of PEG in the choroid plexus. The potentil clinicl implictions of these niml findings re unknown. 98 IMPORTANT SAFETY INFORMATION Contrindictions Reinyn is contrindicted in ptients with known hypersensitivity to Reinyn or its components, including hmster proteins. Wrnings nd Precutions 95 rted their leed control successful Hypersensitivity rections, nphylxis, my occur.s Signs my include % including 1, (defined s excellent or good) ngioedem, chest tightness, difficulty rething, wheezing, urticri, nd itching. nphylctic-type rections occur nd initite Discontinue Reinyn if llergic orn=142 leeding episodes pproprite tretment. Development of neutrlizing ntiodies (inhiitors) to Fctor IX my occur. Monitor ptients for development of fctor IX inhiitors if leeding is not controlled with the recommended dose of Reinyn or if expected Fctor IX ctivity plsm levels re not ttined. Fctor IX ctivity ssy results my vry with the type of ctivted Results shownthromoplstin re from the on-demnd rm regent of the dolescent/ prtil time used. dult tril, in which 15 previously treted dolescent/dult The were use treted of Fctor IX-contining sujects for on-demnd leeds. In 14products sujects, hs een ssocited with thromotic complictions. for thromotic there were totl of 143Monitor leeding episodes. In 1 suject, no nd consumptive cogulopthy when leeding episode dt were recorded. to ptients with liver disese, post-opertively, to neworn dministering Reinyn Results shown or re to sed on leedt ssessment either the infnts, ptients risk ofythromosis or disseminted intrvsculr ptient (for home tretment) cogultion (DIC). or the study investigtor (for tretment under medicl supervision). Bleeds were ssessed Nephrotic syndrome hs een reported using 4-point scle of excellent, good, moderte, or poor. following immune tolernce induction therpy with Fctor IX products in hemophili B ptients with Fctor IX inhiitors, often with history of llergic rections to Fctor IX. The sfety nd efficcy of using Reinyn for immune tolernce induction hve not een estlished. References 1. Reinyn [pckge insert]. Plinsoro, NJ: Novo Nordisk Inc; My Negrier C, Knoe K, Tiede A, Gingrnde P, Møss J. Enhnced phrmcokinetic properties of glycopegylted recominnt fctor IX: first humn dose tril in ptients with hemophili B. Blood. 2011;118(10): Escor MA, Tehrnchi R, Krim FA, et l. Low-fctor consumption for mjor surgery in hemophili B with long-cting recominnt glycopegylted fctor IX. Hemophili. 2017;23(1): Stge APTT-Bsed Fctor Assys. Prcticl-Hemostsis We site. Accessed August 3, Alprolix [pckge insert]. Cmridge, MA: Biogen Inc; Rixuis [pckge insert]. Westlke Villge, CA: Bxlt Helthcre Corportion; Idelvion [pckge insert]. Knkkee, IL: CSL Behring LLC; Ixinity [pckge insert]. Berwyn, PA: Aptevo BioTherpeutics LLC; Benefix [pckge insert]. Phildelphi, PA: Wyeth Phrmceuticls, Inc.; Crco M, Zk M, Krim FA, et l. Noncog et pegol in previously treted children with hemophili B: results from n interntionl open-lel phse 3 tril. J Throm Hemost. 2016;14(8): Collins PW, Young G, Knoe K, et l; prdigm 2 Investigtors. Recominnt long-cting glycopegylted fctor IX in hemophili B: multintionl rndomized phse 3 tril. Blood. 2014;124(26): Swierczewsk M, Lee KC, Lee S. Wht is the future of PEGylted therpies? Expert Opin Emerg Drugs. 2015;20(4): Østergrd H, Bjelke JR, Hnsen L, et l. Prolonged hlf-life nd preserved enzymtic properties of fctor IX selectively PEGylted on ntive N-glycns in the ctivtion peptide. Blood. 2011;118(8): rs. Json lives with hemophili B. Json, 8 yers old, spends his time plying outdoo Development of neutrlizing ntiodies (inhiitors) to Fctor IX my occur. Monitor ptients for development of fctor IX inhiitors if leeding is not controlled with the recommended dose of Reinyn or if expected Fctor IX ctivity plsm levels re not ttined. Fctor IX ctivity ssy results my vry with the type of ctivted prtil thromoplstin time regent used. Plese see dditionl Importnt Sfety Informtion throughout nd on pges 12 nd 13. old, is pilot wh o hikes nd cm ps in his spre tim e. Clyton lives with hemophili B. Importnt Sfety Informtion Wrnings nd Precutions (cont d) Clyton, 34 yers
8 TAKE CONTROL TO A HIGH LEVEL High Fctor Activity 17 % Sustined fter 7 dys with single 40 IU/kg dose in dults with 2% fctor levels 1, Higher Fctor Activity For Longer 2x 5x 10x Recovery rte 2, Hlf-life 2, AUC 2, compred to SHL rfix 2, Bsed upon single initil dose of Reinyn 40 IU/kg in suset of 6 dults upon enrollment in the phse 3 trils. Men FIX ctivity ws 16.8% (one-stge ssy with product-specific stndrd), incrementl recovery ws 2.34 IU/dL per IU/kg nd hlf-life ws 83 hours. Phse 1 study of 15 dults dministered single doses of Reinyn (25, 50 nd 100 IU/kg) nd prior product (50 IU/kg). Comprison of recovery (Reinyn vs SHL rfix: 1.31 vs 0.68 IU/dL per IU/kg), hlf-life (Reinyn vs SHL rfix: 93 vs 19 hours), nd AUC (Reinyn vs SHL rfix: 72 vs 7 [U x h/ml]) re for 7 ptients dministered oth their prior SHL rfix nd Reinyn using one-stge ssy nd product-specific stndrd. Estimted men ctivity for Reinyn ws djusted to dose of 50 IU/kg. Reinyn is not pproved for routine prophylxis. Animls given repet doses of Reinyn showed ccumultion of PEG in the choroid plexus. The potentil clinicl implictions of these niml findings re unknown. INDICATIONS AND USAGE Reinyn, Cogultion Fctor IX (Recominnt), GlycoPEGylted, is recominnt DNA derived cogultion Fctor IX concentrte indicted for use in dults nd children with hemophili B for on demnd tretment nd control of leeding episodes nd periopertive mngement of leeding. Limittions of Use: Reinyn is not indicted for routine prophylxis or for immune tolernce induction in ptients with hemophili B. Plese see dditionl Importnt Sfety Informtion throughout nd on pges 12 nd 13. Novo Nordisk Inc., 800 Scudders Mill Rod, Plinsoro, New Jersey U.S.A. MixPro nd Reinyn re registered trdemrks nd NovoSecure is trdemrk of Novo Nordisk Helth Cre AG. Novo Nordisk is registered trdemrk of Novo Nordisk A/S Novo Nordisk Printed in the U.S.A. USA17BIO02170 Jnury 2018
PNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationCODING AND REIMBURSEMENT GUIDE
ODING ND REIMURSEMENT GUIDE Dignosis, ND, nd ID-10-M 1 illing codes for ogultion Fctor IX (Recominnt), lumin Fusion Protein THE FIRST ND ONLY rfix THERPY THT DELIVERS HIGH-LEVEL PROTETION WITH UP TO 14-DY
More informationUNLOCKING SELF-POTENTIAL
ADVATE is FDA pproved for prophylxis in both dults & children (0-16 yers) 1 UNLOCKING SELF-POTENTIAL Setting Gols Worksheet Plese see pge 3 for ADVATE Indictions nd Detiled Importnt Risk Informtion. Plese
More informationThese highlights do not include all the information needed to use ADVATE safely and effectively. See full prescribing information for ADVATE.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ADVATE sfely nd effectively. See full prescribing informtion for ADVATE. ADVATE [Antihemophilic Fctor
More information7Disconnect the syringe from the. 9Reconnect the syringe to the ADVATE
TROUBLESHOOTING GUIDE The following instructions will guide you through recovering ADVATE if the initil reconstitution procedure does not work. Some steps my need to be repeted from this initil reconstitution
More informationClinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess
More informationEfficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More informationSupplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Powell County. Public Health and Safety Division
Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Yellowstone County. Public Health and Safety Division
Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Lewis & Clark County. Public Health and Safety Division
Community Helth Profile 2015 Lewis & Clrk County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Missoula County. Public Health and Safety Division
Community Helth Profile 2015 Missoul County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationCommunity. Profile Anaconda- Deer Lodge County. Public Health and Safety Division
Community Helth Profile 2015 Ancond- Deer Lodge County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12
More informationSubmitting a Statement of Medical Necessity (SMN) for Humatrope (somatropin for injection)
Sumitting Sttement of Medicl Necessity (SMN) for Humtrope (somtropin for injection) INFORMATION NEEDED FOR FULL SMN FORM SUBMISSION PATIENT INFORMATION: Plese provide Ptient Nme nd Dte of Birth. PRIMARY
More informationBilling and Coding Guide. Hospital Outpatient Department
illing nd oding Guide Hospitl Outptient Deprtment overge, coding, nd pyment in the hospitl outptient deprtment ONPTTRO (ptisirn) received US Food nd Drug dministrtion (FD) pprovl on 10 ug 2018, nd is indicted
More informationThe RUTHERFORD-2 trial in heterozygous FH: Results and implications
The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of
More informationCheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More information2.3. with type 1 diabetes <3 years of age. (8.4)
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use HUMALOG sfely nd effectively. See full prescribing informtion for HUMALOG. HUMALOG (insulin lispro
More informationULTOMIRIS is administered once every 8 weeks a
(rvulizumb-cwvz) for the tretment of dult ptients with proxysml nocturnl hemoglobinuri (PNH) is dministered once every 8 weeks PATIENTS STARTING WITH NO PRIOR TREATMENT FOR PNH THE RECOMMENDED DOSING REGIMEN
More informationBioactive milk components to secure growth and gut development in preterm pigs ESTER ARÉVALO SUREDA PIGUTNET FA1401 STSM
Bioctive milk components to secure growth nd gut development in preterm pigs ESTER ARÉVALO SUREDA PIGUTNET FA1401 STSM STSM Pigutnet FA1401 STSM 03/Septemer 30/Novemer/2017 (3 months) Host: Home: Thoms
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationEFFECTS OF AN ACUTE ENTERIC DISEASE CHALLENGE ON IGF-1 AND IGFBP-3 GENE EXPRESSION IN PORCINE SKELETAL MUSCLE
Swine Dy 22 Contents EFFECTS OF AN ACUTE ENTERIC DISEASE CHALLENGE ON IGF-1 AND IGFBP-3 GENE EXPRESSION IN PORCINE SKELETAL MUSCLE B. J. Johnson, J. P. Kyser, J. D. Dunn, A. T. Wyln, S. S. Dritz 1, J.
More informationSeasonal influenza vaccination programme country profile: Ireland
Sesonl influenz vccintion progrmme country profile: Irelnd 2012 13 Seson Bckground informtion Influenz immunistion policy nd generl fcts bout Irelnd Volume indices of GDP per cpit in 2011 nd 2013 (EU-
More informationProduct Monograph INDICATIONS AND USAGE IMPORTANT RISK INFORMATION WARNING: RISK OF MEDICATION ERRORS AND HEPATOTOXICITY
Product Monogrph INDICATIONS AND USAGE OFIRMEV (cetminophen) injection is indicted for the mngement of mild to moderte pin, mngement of moderte to severe pin with djunctive opioid nlgesics, nd reduction
More informationStart ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4
F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND
More informationCommunity. Profile Carter County. Public Health and Safety Division
Community Helth Profile 2015 Crter County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationPROVEN ANTICOCCIDIAL IN NEW FORMULATION
PROVEN ANTICOCCIDIAL IN NEW FORMULATION Coxidin 100 microgrnulte A coccidiosttic dditive for roilers, chickens rered for lying nd turkeys Contins 100 g of monensin sodium per kg Aville s homogenous grnules
More informationFactor XIII Deficiency (Fibrin Stabilizing Factor Deficiency)
Helthline VOLUME 18 Corm s Continuing Eduction Progrm Fctor XIII Deficiency (Firin Stilizing Fctor Deficiency) Fctor XIII (FXIII) is protein mde y the ody tht stilizes the formtion of lood clot. When FXIII
More informationSTEPS SIMPLE TO INTRODUCE ONCE-DAILY THERAPY TO YOUR ADULT PATIENTS WITH TYPE 2 DIABETES START THE CONVERSATION WITH LOOK INSIDE TO FIND OUT HOW
START THE CONVERSATION WITH SIMPLE STEPS TO INTRODUCE ONCE-DAILY THERAPY TO YOUR ADULT PATIENTS WITH TYPE 2 DIABETES LOOK INSIDE TO FIND OUT HOW Indiction nd Limittions of Use Victoz (lirglutide) injection
More informationEmerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data
Emerging Options for Thromboprophylxis After Orthopedic Surgery: A Review of Clinicl Dt Bob L. Lobo, Phrm.D. In four rndomized, controlled studies of ptients undergoing orthopedic surgery, the ntithrombotic
More informationDebra A. Ignaut, R.N., B.S., C.D.E., and Haoda Fu, Ph.D.
Journl of Dietes Science nd Technology Volume 6, Issue 2, Mrch 2012 Dietes Technology Society TECHNOLOGY REPORT Comprison of Insulin Diluent Lekge Postinjection Using Two Different Needle Lengths nd Injection
More informationInvasive Pneumococcal Disease Quarterly Report July September 2018
Invsive Pneumococcl Disese Qurterly Report July Septemer Introduction Since 17 Octoer 2008, invsive pneumococcl disese (IPD) hs een notifile to the locl Medicl Officer of Helth under the Helth Act 1956.
More informationEYLEA (aflibercept) Injection For Intravitreal Injection Initial U.S. Approval: 2011
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescriing informtion for. (fliercept) Injection For Intrvitrel Injection
More informationXII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV
XII. HIV/AIDS Knowledge bout HIV Trnsmission nd Misconceptions bout HIV One of the most importnt prerequisites for reducing the rte of HIV infection is ccurte knowledge of how HIV is trnsmitted nd strtegies
More informationSponsor / Company: Sanofi Drug substance(s): AVE0005 (aflibercept)
These results re supplied for informtionl purposes only. Prescribing decisions should be mde bsed on the pproved pckge insert in the country of prescription. Sponsor / Compny: Snofi Drug substnce(s): AVE0005
More informationWeight-Based Dosage Regimen: (2.1) Body Weight Range (kg) Loading Dose (mg) Maintenance Dose (mg) greater or equal to 40 to less than 60 2,400 3,000
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (rvulizumb-cwvz) injection, for intrvenous
More informationAddendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)
Addendum to the Evidence Review Group Report on Aripiprzole for the tretment of schizophreni in dolescents (ged 15-17 yers) Produced by Authors Correspondence to Southmpton Helth Technology Assessments
More informationSummary of Package Insert 1
Summry of Pckge Insert 1 For Sttes with Non-Published Policies Indictions Non-infected prtil nd full-thickness skin ulcers due to VSU 2 of greter thn 1 month durtion nd which hve not dequtely responded
More informationWARNING: RISK OF THYROID C CELL TUMORS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use VICTOZA sfely nd effectively. See full prescriing informtion for VICTOZA. VICTOZA (lirglutide) injection,
More informationTarget: 10 mg/day within several days Schizophrenia in adolescents (2.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ZYPREXA sfely nd effectively. See full prescribing informtion for ZYPREXA. ZYPREXA (olnzpine) Tblet
More informationProduct Monograph. Published by
Product Monogrph Pulished y INDICATION AND LIMITATION OF USE JARDIANCE is indicted s n djunct to diet nd exercise to improve glycemic control in dults with type 2 dietes mellitus. JARDIANCE is not recommended
More informationBright Futures Medical Screening Reference Table 2 to 5 Day (First Week) Visit
Bright Futures Medicl Reference Tle 2 to 5 Dy (First Week) Visit Universl Action Metolic nd Verify documenttion of neworn metolic screening results, pproprite rescreening, nd needed follow-up. Document
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 01/2018 FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescriing informtion for. (rifximin) tlets, for orl use Initil U.S.
More informationPrime Enrollees Consumer Watch NHC Patuxent River FY 2016 Defense Health Cost Assessment & Program Evaluation
Prime Enrollees Consumer Wtch NHC Ptuxent River 16 Defense Helth Cost Assessment & Progrm Evlution NHC Ptuxent River: Smple size-1,457 Response rte-1.2% Source: Helth Cre Survey of DoD Beneficiries Inside
More informationDiscuss IBS-D with your doctor
Discuss IBS-D with your doctor Mke sure to tlk out your IBS-D symptoms with your doctor it s n essentil step in deciding on the tretment pln tht s est for your needs. You cn use this converstion guide
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling. Revised: 6/2016 FULL PRESCRIBING INFORMATION: CONTENTS*
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use BASAGLAR sfely nd effectively. See full prescribing informtion for BASAGLAR BASAGLAR (insulin glrgine
More informationEFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE
Swine Dy 21 EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE J. M. DeRouchey, M. D. Tokch, J. L. Nelssen, R. D. Goodbnd, S. S. Dritz 1, J. C. Woodworth, M. J. Webster, B. W.
More informationThe potential future of targeted radionuclide therapy: implications for occupational exposure? P. Covens
The potentil future of trgeted rdionuclide therpy: implictions for occuptionl exposure? Introduction: Trgeted Rdionuclide Therpy (TRT) Systemic tretment Molecule lbelled with rdionuclide delivers toxic
More informationRecommended Dosage Regimen for AVYCAZ (ceftazidime and avibactam) b. AVYCAZ 1.25 grams (ceftazidime 1 gram and avibactam 0.25 grams) every 8 hours
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use AVYCAZ sfely nd effectively. See full prescribing informtion for AVYCAZ. AVYCAZ (ceftzidime nd vibctm)
More informationPresented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE
Seven-Yer Interim Results from the ESPRIT 10-Yer Postmrketing Surveillnce Registry of Adlimumb for Moderte to Severe Psorisis Frncisco Kerdel, 1 Aln Menter, 2 Jshin J. Wu, 3 Mreike Bereswill, 4 Dilek Arikn,
More informationPatient-Controlled Transdermal Fentanyl Versus Intravenous Morphine Pump After Spine Surgery
Ptient-Controlled Trnsderml Fentnyl Versus Intrvenous Morphine Pump After Spine Surgery Emily M. Lindley, PhD; Kenneth Millign, BS; Ryn Frmer, MD; Evlin L. Burger, MD; Viks V. Ptel, MD bstrct Ptient-controlled
More informationTHE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS
THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS John F. Ptience nd Doug Gillis SUMMARY
More informationPatients with cancer are at an increased
Risk of Cncer-Associted Thrombosis nd Bleeding in Veterns With Mlignncy Who Are Receiving Direct Orl Anticogulnts Mtthew Stnkowicz, PhrmD; Megn Bnszynski, PhrmD, BCOP; nd Russell Crwford, BPhrm, BCOP The
More informationResults. Table 1: Demographic and Baseline Characteristics, Open-Label Safety Population Prior Double-Blind OC/APAP ER (n=77)
Open-Lbel Extension of Rndomized, Double-Blind, Plcebo-Controlled, Phse 3 Study of the Sfety nd Anlgesic Efficcy of MNK-795 Oxycodone/Acetminophen Extended-Relese (OC/APAP ER) Tblets in n Acute Pin Model
More information1 Indications and Usage
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ERBITUX sfely nd effectively. See full prescriing informtion for ERBITUX. ERBITUX (cetuxim) injection,
More informationMay 28, Congressional Requesters
United Sttes Government Accountbility Office Wshington, DC 20548 My 28, 2010 Congressionl Requesters Subject: Federl Funds: Fiscl Yers 2002-2009 Obligtions, Disbursements, nd Expenditures for Selected
More informationEffect on Glycemic, Blood Pressure, and Lipid Control according to Education Types
Originl Article http://dx.doi.org/10.4093/dmj.2011.35.6.580 pissn 2233-6079 eissn 2233-6087 D I A B E T E S & M E T A B O L I S M J O U R N A L Effect on Glycemic, Blood Pressure, nd Lipid Control ccording
More informationUsing Paclobutrazol to Suppress Inflorescence Height of Potted Phalaenopsis Orchids
Using Pcloutrzol to Suppress Inflorescence Height of Potted Phlenopsis Orchids A REPORT SUBMITTED TO FINE AMERICAS Linsey Newton nd Erik Runkle Deprtment of Horticulture Spring 28 Using Pcloutrzol to Suppress
More information* * * * * liver kidney ileum. Supplementary Fig.S1
Supplementry Fig.S1 liver kidney ileum Fig.S1. Orlly delivered Fexrmine is intestinlly-restricted Mice received vehicle or Fexrmine (100mg/kg) vi per os (PO) or intrperitonel (IP) injection for 5 dys (n=3/group).
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 10/2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (ipilimumb) injection, for intrvenous use
More informationAbstract. Background. Aim. Patients and Methods. Patients. Study Design
Impct of the Use of Drugs nd Substitution Tretments on the Antivirl Tretment of Chronic Heptitis C: Anlysis of Complince, Virologicl Response nd Qulity of Life (CHEOBS). Melin, 1 J.-. Lng, D. Ouzn, 3 M.
More informationDiabetes affects 29 million Americans, imposing a substantial
CLINICAL Comprtive Effectiveness nd Costs of Insulin Pump Therpy for Dibetes Ronld T. Ackermnn, MD, MPH; Amish Wlli, MD, MS; Rymond Kng, MA; Andrew Cooper, MPH; Theodore A. Prospect, FSA, MAAA; Lewis G.
More informationNonpharmacologic Interventions for Treatment-Resistant Depression in Adults Executive Summary
Comprtive Effectiveness Review Numer 33 Effective Helth Cre Progrm Nonphrmcologic Interventions for Tretment-Resistnt Depression in Adults Executive Summry Bckground Mjor depressive disorder (MDD) is common
More informationShort-term therapy with lasting relief 2
# 1 PRESCRIBED MEDICATION APPROVED FOR IBS-D 1 * Short-term therpy with lsting relief 2 provided up to 6 months of symptom relief with 2-week tretment 2 Rnge of 6 to 24 weeks; medin of 10 weeks. Convenient
More informationTRULICITY TRU-0003-USPI _TRU-0002-MG , 8 X 10.5 PRINTER VERSION 1 OF 8
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescriing informtion for. (dulglutide) injection, for sucutneous use
More informationEconomic evaluation of sublingual vs subcutaneous allergen immunotherapy Jitka Pokladnikova, MSc, Pharm*; Irena Krcmova, MD ; and Jiri Vlcek, PhD*
Economic evlution of sublingul vs subcutneous llergen immunotherpy Jitk Pokldnikov, MSc, Phrm*; Iren Krcmov, MD ; nd Jiri Vlcek, PhD* Bckground: Sublingul llergen immunotherpy (SLIT) is commonly used lterntive
More informationHealth Coaching: A Preliminary Report on the Effects in Traumatic Brain Injury/Polytrauma Patients
ORIGINAL RESEARCH Helth Coching: A Preliminry Report on the Effects in Trumtic Brin Injury/Polytrum Ptients Esmerld Mdrigl, MSW; Mx Gry, BA; Molly A. Timmermn, DO; Ttin Orozco, PhD; Dine Cowper Ripley,
More informationIn the treatment of cardiovascular disease (CVD), national
n report n Beyond LDL Cholesterol: The Role of Elevted Triglycerides nd Low HDL Cholesterol in Residul CVD Risk Remining After Sttin Therpy Peter Algon Jr, MD, FACC In the tretment of crdiovsculr disese
More informationThe effect of encapsulated butyric acid and zinc on performance, gut integrity and meat quality in male broiler chickens 1
The effect of encpsulted utyric cid nd zinc on performnce, gut integrity nd met qulity in mle roiler chickens 1 Astrct This study evluted the impct of encpsulted utyric cid nd zinc (ButiPEARL Z) on performnce
More information58 % 50 % REDUCTION IN RISK OF OVERT HE RECURRENCE 1
FOR ADULT PATIENTS WITH OVERT HEPATIC ENCEPHALOPATHY (HE) significntly reduced the risk of overt HE recurrence nd HE-relted hospitliztions 1 58 % 50 % REDUCTION IN RISK OF OVERT HE RECURRENCE 1 REDUCTION
More informationINVEGA SUSTENNA (paliperidone palmitate) extended-release injectable
(pliperidone plmitte) extended-relese injectble suspension, for intrmusculr use HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively.
More informationEffects of physical exercise on working memory and prefrontal cortex function in post-stroke patients
Effects of physicl exercise on working memory nd prefrontl cortex function in post-stroke ptients M Moriy, C Aoki, K Sktni Grdute School of Helth Sciences Reserch, Mjor of Physicl Therpy, TeikyoHeisei
More informationPatient Monitoring Checklist
Ptient Monitoring Checklist Ptient nme Dte This checklist is intended for nurses or other helthcre professionls (HCPs) to use prior to dosing ech ptient nd t ny follow-up visits or clls with the ptient
More informationBilling for Xofigo (radium Ra 223 dichloride) Injection and Administration in Separate Sites of Care
Billing for Xofigo (rdium R 223 dichloride) Injection nd Administrtion in Seprte Sites of Cre Providers re solely responsile for confirming pproprite coverge, coding nd reimursement nd ensuring tht ll
More informationAntiviral Therapy 2015; 20: (doi: /IMP2874)
Antivirl Therpy 25; 2:79 79 (doi:.385/imp2874) Originl rticle Single dose permivir for the tretment of cute sesonl influenz: integrted nlysis of efficcy nd sfety from two plcebo-controlled trils Richrd
More informationAntiviral Therapy 2015; 20: (doi: /IMP2920)
Antivirl Therpy 2015; 20:397 405 (doi: 10.3851/IMP2920) Originl rticle Sfety, tolerbility nd phrmcokinetics of dorvirine, novel HIV non-nucleoside reverse trnscriptse inhibitor, fter single nd multiple
More information10-15 mg/day 15 mg/day 30 mg/day. 2-5 mg/day 5-10 mg/day 15 mg/day. 2 mg/day 5-10 mg/day 15 mg/day. 30 mg/day injected IM
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ABILIFY sfely nd effectively. See full prescribing informtion for ABILIFY. Tblets ABILIFY DISCMELT
More informationMecadox. Improves pig performance in a wide range of health and growing conditions. (Carbadox) Talk With a Phibro Expert:
SWINE (Crbdox) Improves pig performnce in wide rnge of helth nd growing conditions The Advntge Over the yers, medicted feed dditive hs proven to be cost-effective mngement tool for improving pig performnce
More informationIMPORTANT Reminders for Patients. IMPORTANT Information for Doctors/Nurses
Monitor Your Signs nd Symptoms (nivolum) is prescription medicine used in comintion with YERVOY (ipilimum) to tret type of skin cncer clled melnom tht hs spred or cnnot e removed y surgery (dvnced melnom).
More informationkey words: chronic obstructive pulmonary disease, beta agonists, Medicare, health care costs, health care utilization
reserch report Helth Cre Use nd Costs Among Medicre Ptients With Chronic Obstructive Pulmonry Disese Treted With Short-Acting Bet Agonists or Long-Acting Bet Agonists Flvi Ejzykowicz, PhD; 1 Vmsi K Bollu,
More informationOptimisation of diets for Atlantic cod (Gadus morhua) broodstock: effect of arachidonic acid on egg & larval quality
Optimistion of diets for Atlntic cod (Gdus morhu) roodstock: effect of rchidonic cid on egg & lrvl qulity Dr Gordon Bell, Ms. An Blnco, Dr Bill Roy, Dr Derek Roertson, Dr Jim Henderson nd Mr Richrd Prickett,
More informationXALKORI (crizotinib) Is Available Through Specialty Pharmacies
XALKORI (crizotinib) Is Avilble Through Specilty Phrmcies Specilty Phrmcy Ordering Process The Provider s Office Submits XALKORI prescriptions to the specilty phrmcy vi: Phone Fx Internet Submits ny supporting
More informationOral anticoagulant therapies: Balancing the risks
Orl nticogulnt therpies: Edith A. Nutescu Firin clot formtion (i.e., clotting) is the result of the conversion of firinogen to firin, the lst step in the finl common pthwy of the clotting cscde, which
More informationReports of cases of AIDS, HIV infection, and HIV/AIDS 1
Reports of cses of AIDS, HIV infection, nd HIV/AIDS 1 The HIV/AIDS Surveillnce Report is published nnully by the Division of HIV/AIDS Prevention Surveillnce nd Epidemiology, Ntionl Center for HIV, STD,
More informationManagement and Outcomes of Binge-Eating Disorder in Adults: Current State of the Evidence
Clinicin Summry Mentl Helth Eting Disorders Mngement nd Outcomes of Binge-Eting Disorder in Adults: Current Stte of the Evidence Focus of This Summry This is summry of systemtic review evluting the evidence
More informationImpact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting
Impct of Phrmcist Intervention on Dibetes Ptients in n Ambultory Setting Julie Stding, PhrmD, CDE, Jmie Herrmnn, PhrmD, Ryn Wlters, MS, Chris Destche, PhrmD, nd Aln Chock, PhrmD Dibetes is the seventh-leding
More informationAnemia in pediatric hemodialysis patients: Results from the 2001 ESRD Clinical Performance Measures Project
Kidney Interntionl, Vol. 64 (2003), pp. 1120 1124 Anemi in peditric hemodilysis ptients: Results from the 2001 ESRD Clinicl Performnce Mesures Project DIANE L. FRANKENFIELD, ALICA M. NEU, BRADLEY A. WARADY,
More informationFor Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
For Adults With Previously Treted Advnced Non-Smll Cell Lung Cncer (NSCLC) individuls depicted re models used for illustrtive purposes only. It cn be overwhelming to lern tht your previously treted dvnced
More informationY. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3
Greter remission rtes in ptients with erly versus long-stnding disese in biologic-nive rheumtoid rthritis ptients treted with btcept: post hoc nlysis of rndomised clinicl tril dt Y. Yzici 1, D. Moniz Reed
More informationWSU Tree Fruit Research and Extension Center, Wenatchee (509) ext. 265;
FINAL REPORT WTFRC Project # AH-1-5 WSU Project # 13C-355-3 Project title: PI: Orgniztion: Coopertors: of Sunburn in Apples with RAYNOX Lrry Schrder, Horticulturist WSU Tree Fruit Reserch nd Extension
More informationHERCEPTIN (trastuzumab) Intravenous Infusion Initial U.S. Approval: 1998
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescriing informtion for. HERCEPTIN (trstuzum) Intrvenous Infusion
More informationEffect of supplemental fat from dried distillers grains with solubles or corn oil on cow performance, IGF-1, GH, and NEFA concentrations 1
Effect of supplementl ft from dried distillers grins with solules or corn oil on cow performnce, IGF-1, GH, nd NEFA concentrtions 1 Aigil Brtosh 2, Cody Wright 3, Aimee Wertz-Lutz 4, nd George Perry 5
More informationA Four-System Comparison of Patients With Chronic Illness: The Military Health System, Veterans Health Administration, Medicaid, and Commercial Plans
MILITARY MEDICINE, 174, 9:936, 2009 A Four-System Comprison of Ptients With Chronic Illness: The Militry Helth System, Veterns Helth Administrtion, Medicid, nd Commercil Plns Teres B. Gibson, PhD * ; Todd
More informationIf Eligible, Get EFFEXOR XR Co-Pay Card Savings on Your Branded Prescription*
If Eligible, Get EFFEXOR XR Co-Py Crd Svings on Your Brnded Prescription* REMEMBER: You must be prescribed brnd-nme EFFEXOR XR to receive the monthly svings tht come with your Co-Py Crd. *Terms nd conditions
More informationRelationship Between Hospital Performance on a Patient Satisfaction Survey and Surgical Quality
Reserch Originl Investigtion Reltionship Between Hospitl Performnce on Ptient Stisfction Survey nd Surgicl Qulity Greg D. Scks, MD, MPH; Elise H. Lwson, MD, MSHS; Aron J. Dwes, MD; Mrci M. Russell, MD;
More information